Satellos Bioscience Inc. Common Stock (MSLE) - Net Assets
Based on the latest financial reports, Satellos Bioscience Inc. Common Stock (MSLE) has net assets worth $59.84 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($65.69 Million) and total liabilities ($5.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset allocation strategy of Satellos Bioscience Inc. Common Stock to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $59.84 Million |
| % of Total Assets | 91.09% |
| Annual Growth Rate | 14.35% |
| 5-Year Change | 237.96% |
| 10-Year Change | 1091.95% |
| Growth Volatility | 303.93 |
Satellos Bioscience Inc. Common Stock - Net Assets Trend (2007–2025)
This chart illustrates how Satellos Bioscience Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market cap of Satellos Bioscience Inc. Common Stock.
Annual Net Assets for Satellos Bioscience Inc. Common Stock (2007–2025)
The table below shows the annual net assets of Satellos Bioscience Inc. Common Stock from 2007 to 2025. Also explore MSLE net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $27.78 Million | -41.24% |
| 2024-12-31 | $47.28 Million | +16.25% |
| 2023-12-31 | $40.67 Million | +1119.48% |
| 2022-12-31 | $3.34 Million | -59.43% |
| 2021-12-31 | $8.22 Million | +4561.90% |
| 2020-12-31 | $-184.25K | -127.15% |
| 2019-12-31 | $678.67K | +209.02% |
| 2018-12-31 | $-622.52K | -156.43% |
| 2017-12-31 | $1.10 Million | -52.68% |
| 2016-12-31 | $2.33 Million | -38.19% |
| 2015-12-31 | $3.77 Million | -28.34% |
| 2014-12-31 | $5.26 Million | +326.77% |
| 2013-12-31 | $1.23 Million | -39.98% |
| 2012-12-31 | $2.05 Million | -23.50% |
| 2011-12-31 | $2.69 Million | +11.85% |
| 2010-12-31 | $2.40 Million | -44.29% |
| 2009-12-31 | $4.31 Million | +381.59% |
| 2008-12-31 | $894.78K | -63.99% |
| 2007-12-31 | $2.49 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Satellos Bioscience Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7369118200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $85.83 Million | 308.91% |
| Other Comprehensive Income | $-1.72 Million | -6.19% |
| Other Components | $25.65 Million | 92.30% |
| Total Equity | $27.78 Million | 100.00% |
Satellos Bioscience Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Satellos Bioscience Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bangkok Aviation Fuel Services Public Company Limited
BK:BAFS
|
$198.70 Million |
|
Sangsin Energy Display Precision Co.Ltd
KQ:091580
|
$198.71 Million |
|
Intops Co. Ltd
KQ:049070
|
$198.73 Million |
|
Kimteks Poliuretan Sanayi ve Ticaret AS
IS:KMPUR
|
$198.74 Million |
|
Studsvik AB
ST:SVIK
|
$198.56 Million |
|
NORTHERN OCEAN LTD.
F:4JO
|
$198.30 Million |
|
Nucleus Software Exports Limited
NSE:NUCLEUS
|
$198.26 Million |
|
Plum Acquisition Corp. IV Class A Ordinary Shares
NASDAQ:PLMK
|
$198.24 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Satellos Bioscience Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 47,284,331 to 27,784,000, a change of -19,500,331 (-41.2%).
- Net loss of 24,873,000 reduced equity.
- Other comprehensive income decreased equity by 1,568,801.
- Other factors increased equity by 6,941,470.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-24.87 Million | -89.52% |
| Other Comprehensive Income | $-1.57 Million | -5.65% |
| Other Changes | $6.94 Million | +24.98% |
| Total Change | $- | -41.24% |
Book Value vs Market Value Analysis
This analysis compares Satellos Bioscience Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.41x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.07x to 0.41x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | $131.35 | $9.36 | x |
| 2008-12-31 | $10.70 | $9.36 | x |
| 2009-12-31 | $35.01 | $9.36 | x |
| 2010-12-31 | $14.10 | $9.36 | x |
| 2011-12-31 | $15.36 | $9.36 | x |
| 2012-12-31 | $9.96 | $9.36 | x |
| 2013-12-31 | $4.81 | $9.36 | x |
| 2014-12-31 | $14.95 | $9.36 | x |
| 2015-12-31 | $10.72 | $9.36 | x |
| 2016-12-31 | $6.62 | $9.36 | x |
| 2017-12-31 | $3.13 | $9.36 | x |
| 2018-12-31 | $-1.77 | $9.36 | x |
| 2019-12-31 | $1.33 | $9.36 | x |
| 2020-12-31 | $-2.49 | $9.36 | x |
| 2021-12-31 | $4.13 | $9.36 | x |
| 2022-12-31 | $1.12 | $9.36 | x |
| 2023-12-31 | $5.65 | $9.36 | x |
| 2024-12-31 | $4.94 | $9.36 | x |
| 2025-12-31 | $22.84 | $9.36 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Satellos Bioscience Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -89.52%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.15x
- Recent ROE (-89.52%) is above the historical average (-132.33%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -207.90% | 0.00% | 0.00x | 1.31x | $-5.42 Million |
| 2008 | -268.06% | 0.00% | 0.00x | 1.43x | $-2.49 Million |
| 2009 | -53.61% | 0.00% | 0.00x | 1.07x | $-2.74 Million |
| 2010 | -130.03% | -3104.66% | 0.04x | 1.12x | $-3.36 Million |
| 2011 | -38.35% | 0.00% | 0.00x | 1.09x | $-1.30 Million |
| 2012 | -177.72% | 0.00% | 0.00x | 1.47x | $-3.86 Million |
| 2013 | -436.49% | 0.00% | 0.00x | 3.03x | $-5.51 Million |
| 2014 | -36.50% | 0.00% | 0.00x | 1.29x | $-2.45 Million |
| 2015 | -47.48% | 0.00% | 0.00x | 1.03x | $-2.17 Million |
| 2016 | -64.39% | 0.00% | 0.00x | 1.06x | $-1.73 Million |
| 2017 | -113.80% | 0.00% | 0.00x | 1.27x | $-1.37 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.63 Million |
| 2019 | -293.38% | 0.00% | 0.00x | 2.22x | $-2.06 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.56 Million |
| 2021 | -146.75% | 0.00% | 0.00x | 1.19x | $-12.99 Million |
| 2022 | -339.46% | 0.00% | 0.00x | 1.84x | $-11.66 Million |
| 2023 | -29.45% | 0.00% | 0.00x | 1.09x | $-16.04 Million |
| 2024 | -41.41% | 0.00% | 0.00x | 1.08x | $-24.31 Million |
| 2025 | -89.52% | 0.00% | 0.00x | 1.15x | $-27.65 Million |
Industry Comparison
This section compares Satellos Bioscience Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $161,895,707
- Average return on equity (ROE) among peers: -42.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Satellos Bioscience Inc. Common Stock (MSLE) | $59.84 Million | -207.90% | 0.10x | $198.59 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $109.30 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $170.10 Million | -16.06% | 0.05x | $310.51 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-12.35 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.35 Billion |
| Arbutus Biopharma Corp (ABUS) | $38.29 Million | -30.60% | 0.11x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.31 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $199.76 Million | -82.32% | 0.11x | $4.61 Billion |
About Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small m… Read more